We are live on ! Find out more
YARW icon

Yarrow Bioscience

34 hedge funds and large institutions have $1.33M invested in Yarrow Bioscience in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 5

23% less funds holding

Funds holding: 44 → 34 (-10)

37.64% less ownership

Funds ownership: 53.26% → 15.61% (-38%)

59% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 17

86% less capital inflows, than outflows

Capital inflows: $1.43M | Capital outflows: $9.9M

Holders
34
Holders Change
-10
Holders Change %
-22.73%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
7
Reduced
5
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

YARW Hedge Fund Activity: Q3 2025 in Review

34 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience (YARW) for Q3 2025, worth a combined $1.33M — down 90% from $13.4M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of YARW and 7 opened new positions — a net loss of 10 holders — while 5 trimmed existing stakes and 7 added.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $557K. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.26M sold.

  • 34 institutional investors held Yarrow Bioscience (YARW) as of Q3 2025, down from 44 in Q2 2025.
  • Funds reported $1.33M of Yarrow Bioscience stock for Q3 2025, down 90% quarter-over-quarter.
  • 7 funds opened new Yarrow Bioscience positions in Q3 2025 and 17 closed out, a net change of -10 holders.
  • The largest Yarrow Bioscience buyer in Q3 2025 was Baker Bros. Advisors, an estimated $557K added.
  • The largest Yarrow Bioscience seller in Q3 2025 was Cormorant Asset Management, an estimated $2.26M sold.

Based on aggregated 13F filings for Q3 2025.